Xultophy: combination therapy for the treatment of type 2 diabetes
نویسندگان
چکیده
منابع مشابه
NEW DRUG APPROVALS Xultophy for Type-2 Diabetes
NEW DRUG APPROVALS Xultophy for Type-2 Diabetes The FDA has approved Xultophy 100/3.6 (insulin degludec 100 units/mL and liraglutide 3.6 mg/mL injection, Novo Nordisk). The product, a once-daily combination of Tresiba (insulin degludec injection) and Victoza (liraglutide injection), is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes that i...
متن کاملCombination lipid therapy in type 2 diabetes.
To the Editor: In the Action to Control Car diovascular Risk in Diabetes (ACCORD) trial (ClinicalTrials.gov number, NCT00000620) report ed on by Ginsberg et al. (April 29 issue),1 the use of fenofibrate in patients with type 2 diabetes mellitus who were receiving simvastatin and who were at high risk for cardiovascular disease great ly reduced triglyceride levels but hardly increased levels ...
متن کاملPharmacogenomic approach in type 2 diabetes treatment
Introduction: Type 2 diabetes (T2D) is chronic health caused by the interaction between genetic and environmental factors that results in high blood glucose. The evidence-based guidelines for diabetes management are mainly based on lifestyle changes, control of risk factors, and the management of blood glucose levels. Although numerous antidiabetic agents have been developed over time, T2D trea...
متن کاملThe synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes.
OBJECTIVE To investigate the efficacy and safety of miglitol in combination with metformin in improving glycemic control in outpatients in whom type 2 diabetes is insufficiently controlled by diet alone. RESEARCH DESIGN AND METHODS In this multicenter, double-blind, placebo-controlled study, 324 patients with type 2 diabetes were randomized, after an 8-week placebo run-in period, to treatment...
متن کاملOptimizing combination treatment in the management of type 2 diabetes
Obtaining the suggested glycemic control is the most important achievement in order to prevent cardiovascular complications in patients with type 2 diabetes. Monotherapy often fails after a period of treatment, so that multiple drugs are needed to achieve effective glycemic control. A number of oral glucose lowering drugs is now available such as metformin, sulfonylureas, non-sulfonylureas secr...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Prescriber
سال: 2015
ISSN: 0959-6682
DOI: 10.1002/psb.1382